Loading clinical trials...
Loading clinical trials...
A First-in-human (FIH) Clinical Trial to Investigate the Human Monoclonal Antibody NG004, Administrated Intrathecally in Acute Spinal Cord Injury (SCI) Patients
Conditions
Interventions
NG004
Locations
6
Germany
Klinik für Querschnittgelähmte, Klinikum Bayreuth
Bayreuth, Germany
Zentrum für Rückenmarkverletzte und Klinik für Orthopädie, BG Klinikum Bergmannstrost
Halle, Germany
Klinik für Paraplegiologie, Universitätsklinikum Heidelberg
Heidelberg, Germany
Zentrum für Rückenmarksverletzte, Unfallklinik Murnau
Murnau am Staffelsee, Germany
Swiss Paraplegic Centre
Nottwil, Switzerland
Universitätsklinik Balgrist
Zurich, Switzerland
Start Date
December 18, 2024
Primary Completion Date
September 1, 2026
Completion Date
September 1, 2026
Last Updated
February 10, 2025
NCT05386108
NCT05508789
NCT06954610
NCT06871969
NCT05023772
NCT04286516
Lead Sponsor
NovaGo Therapeutics AG
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions